Ukraine’s pharmaceutical market in the first half of 2022 fell by 27% in volume and 20% in value due to the war compared to the same period last year, the relevant data are given in the report of the SMD company “Ukraine’s pharmaceutical market in the first half 2022. The market in the flames of war.”
At the same time, the company does not provide absolute indicators in the document.
According to the company, the main market drop during this period occurred in April and amounted to 50% in volume and 51% in value compared to April 2021.
At the same time, SMD experts note the significant impact of migration and population decline on the situation in the pharmaceutical market.
At the same time, the company pays attention to some stabilization of the situation in May, as well as to a slight market growth in monetary terms over the past months, which reflects the increase in drug prices.
In addition, the company’s experts emphasize that in the first half of this year, the actual consumption of medicines was higher than the monitoring showed due to the significant amount of humanitarian aid transferred.
At the same time, the share of public procurement was stable in terms of volume – 21% versus 20% in the first half of 2021, but increased from 25% to 30% in value terms due to a larger share of centralized purchases of high-priced products.
In addition, the company notes significant changes in the regional distribution. In particular, the largest reduction in consumption and market share is noted in Kharkiv, Kyiv region (without Kyiv city), as well as in Chernihiv, Kherson, Mykolaiv and Sumy regions.
The largest increase in market share during the war was demonstrated by Lviv region, Kyiv city, Dnipropetrovsk, Ivano-Frankivsk, Volyn, Zakarpattia, Ternopil and other western regions.
At the same time, in Odesa and central regions of Ukraine, there was a slight increase in market share (0.5-0.6%).
“The change in the share of regional markets was influenced not only by internal migration of the population, but also by the work of large military clinics that consumed a significant amount of drugs in certain regions,” the company emphasizes.
Experts also note an increase in the share of domestically produced drugs despite serious damage to some capacities – 38.4% in January-June of this year versus 37% in 2021 as a whole.
According to the study, Sinovac became the leader of the pharmaceutical market during the analyzed period thanks to the purchase of a vaccine against COVID-19.
Without taking this company into account, the position of the market leader, despite a significant reduction in sales, is maintained by Farmak, the second place is taken by the pharmaceutical company Darnitsa, and the third by Yuria-Pharm.
Sanofi and Arterium, respectively, took fourth and fifth positions in the ranking of pharmaceutical market leaders for the first half of the year.
The pharmaceutical market of Ukraine over 2020 will grow by 4-6%, the chairman of the board of directors of Darnitsa Pharmaceutical Group, Dmytro Shymkiv, predicts.
“According to analysts, over 2020 we will see growth in the range of 4-6%. The market is expected to grow by about 6-11% in 2021,” he said in an interview with Interfax-Ukraine.
Shymkiv noted that “the Ukrainian pharmaceutical industry has a great potential inherent in the previous period: over the past five years, the industry has grown, on average, by 12% annually.”
At the same time, he predicts that Darnitsa will end 2020 with the indicators of last year.
“In both Ukrainian and international pharmaceutical sectors, this can be considered a serious result for an unexpectedly turbulent year,” he said.
